The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—’PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION
BETHESDA, MD—January 14, 2021—Precision Medicine Group (“PMG”) announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies. Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma’s unique expertise to Precision’s suite of end-to-end cell and gene therapy capabilities to support development and commercialization.
PRECISION FOR MEDICINE PARTNERS WITH KARYOPHARM THERAPEUTICS TO INITIATE NEW GLOBAL CLINICAL TRIAL TO TREAT PATIENTS WITH COVID-19
— First Study of an XPO1 Inhibitor to Treat Patients with Severe Viral Infections
— Precision for Medicine Responsible for Clinical Trial Management in Europe
BUDAPEST, April 22, 2020 – Precision for Medicine, a pioneer in the design, development and execution of biomarker-informed clinical studies and complex data management, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) to help conduct the first global randomized clinical trial for low dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19.
REBRANDING LAUNCH EMPHASIZES COMPANY’S INVESTMENT AND PRIORITY IN UNIFYING EXPERTISE AND ACCELERATING CULTURE OF COLLABORATION
New York, NY – April 7th, 2020 – Precision Value & Health, part of Precision Medicine Group, today announced a comprehensive rebranding that includes new names, new logos and updated positioning to accurately reflect its expanded offerings in 2020. To communicate this new positioning and re-aligned capabilities, the company has also rolled out new websites for Precision Value & Health as well as its sub-brands.
VETERAN STRATEGIST AND LEADER TO GUIDE THE CONTINUED EXPANSION AND GROWTH
OF PRECISION’S INDUSTRY-LEADING GLOBAL CLINICAL TRIALS SOLUTIONS
January 27, 2020– New York, NY – Precision for Medicine, the first comprehensive, fully-integrated biomarker-driven clinical research services organization, today announced that veteran healthcare leader Mairead Kehoe has been named its new Executive Vice President, responsible for overseeing its global clinical solutions delivery.
In adding Ms. Kehoe’s expertise and leadership, Precision builds upon its novel, biomarker-driven approach— integrating translational sciences and clinical trials— and strengthens its industry-leading position as experts in early development and late-phase trials for innovative life changing therapies. Precision’s growing global footprint now includes 34 offices worldwide with nearly 2000 employees, and is managing trals in over 35 countries.
Ms. Kehoe joins Precision with 25+ years of industry experience from biotech, CRO and biopharma clinical research industry, spanning all aspects of global clinical development. Her experience includes management and leadership positions focused on the strategic planning and quality conduct of global clinical programs encompassing end-to-end drug development operations, from early development through to product approval – seeing first-hand the positive impact of quality and thoughtful clinical development.
Most recently, Ms. Kehoe held the position of Corporate Vice President of Global Clinical Quality Assurance (GCP) & Data Sharing/Disclosure at Celgene Corp. where she was responsible for the global leadership of the GCP programs for Early Development, R&D and Medical Affairs. Prior to this, Mairead held the position of Vice President, Global Clinical Operations and was responsible for the strategic planning, oversight and leadership for the global Clinical Operations functions at Celgene. Prior to joining Celgene, Ms. Kehoe was the Executive Director, Global Clinical Operations for i3/Ingenix and was responsible for the strategic and operational leadership across core therapeutic areas.
Guiding the delivery of Precision’s global clinical solutions, Ms. Kehoe will continue to evolve Precision’s integrated team approach, utilizing clinical science, exceptional data integrity and quality operations to facilitate timely and targeted endpoint-driven decision making– providing clients with a unique, end-to-end operating platform.
Discussing Ms. Kehoe’s unique experience and qualifications, Pat Devitt, President, Precision for Medicine, Clinical Solutions adds, “We are extremely fortunate to be adding a veteran leader such as Mairead to drive the growth and expansion of our global clinical solutions offering— expertly guiding us in our growth strategy as well as in the proactive planning and quality execution of programs and cross-organizational processes.”
Expressing her enthusiasm for the opportunity, Ms. Kehoe explains, “I am very excited to be part of the Precision for Medicine Team. It is rewarding to work alongside such a group of highly experienced and passionate professionals focused on quality drug development, with the common goal of bringing forward meaningful treatment options for patients and their families dealing with challenging diseases.”
About Precision for Medicine,
Precision for Medicine, part of Precision Medicine Group, is the first comprehensive, fully integrated CRO devoted to oncology and rare disease innovation. With over 1900 experts in 34 offices worldwide, Precision offers novel clinical trial designs, industry-leading operational and medical experts, and advanced biomarker solutions for pharma and biotech innovators. For more information, please visit: https://www.precisionmedicinegrp.com/pfmord/.
Precision Medicine Group Media Relations
SUBSCRIBERS CAN NOW IMMEDIATELY UNMASK AND CONNECT
COMPLEX PAYER INFORMATION HIDDEN IN DATA SETS,
DELIVERING UNRIVALLED ANALYTIC INSIGHTS
BETHESDA, MD – January 23, 2019 — Precision Xtract, part of Precision Value & Health, today announced the launch of a new subscription-based translation service, providing its clients with the ability to accurately connect and unmask health insurance BIN-PCN Group numbers contained in specialty pharmacy, direct reporting pharmacy, hub, copay card and other data sources. The new service, available for preview at www.BPGLookup.com, unlocks a previously unattainable level of analytic insights to multiple stakeholders, including pharmaceutical manufacturers, specialty pharmacies, payers, data aggregators, PBMs, EMR vendors, and hospital systems.
PRECISION’S UNIQUE COMBINATION OF CLINICAL SERVICES AND TRANSLATIONAL SCIENCES
IS RECOGNISED FOR BIOTECH INDUSTRY INNOVATION
5 December, 2019 – London, UK – Precision for Medicine, Oncology and Rare Disease, the first comprehensive, fully integrated CRO devoted to oncology and rare disease innovation, announced its recognition as Best Specialist CRO at this year’s OBN Awards. The winners were announced at the 2019 OBN Awards ceremony on 7 November at the University of Oxford.
NEW STATE-OF-THE-ART FACILITY DRAMATICALLY INCREASES CAPACITY FOR CLINICAL TRIALS AND OFFERS CLIENTS FIRST-OF-ITS-KIND CELL PROFILING CAPABILITIES COMBINING EPIGENETICS AND FLOW CYTOMETRY
BERLIN, GERMANY – 27 NOVEMBER 2019 – Precision for Medicine, part of Precision Medicine Group, today announced that they have opened a new 1,600 m2 Berlin-based laboratory, for the first time combining its proprietary Epiontis ID™ epigenetic immune-monitoring technology with advanced flow cytometry capabilities, along with a full-service biorepository and cell processing laboratory. Focusing on the rapidly growing immuno-oncology and neuroimmunology markets, the new lab creates a 10-fold increase in Precision’s European capacity. In addition, the new dedicated facility boosts Precision’s full-time European workforce to well over 300 employees and bolsters its expanding clinical trials footprint that now includes offices in Edinburgh, Paris, Geneva, Budapest, Bucharest, Bratislava, and Belgrade and additional staff throughout Europe and the United Kingdom.
MENLO PARK, CA and HOUSTON, November 5, 2019 – Akoya Biosciences, The Spatial Biology Company™ today announced a strategic alliance with Precision for Medicine (formerly ApoCell), a pioneer in customized biomarker solutions, to develop proprietary liquid biopsy and tissue biomarker tests using Akoya’s Vectra® Polaris™ System. By combining the Vectra Polaris system with Precision for Medicine’s ApoStream® technology, the collaboration is designed to advance immuno-oncology candidates in clinical trials using both tumor biopsies and liquid biopsies to generate data required for assessing drug efficacy and validation of companion diagnostics (CDx).
“We are very excited to be the first commercial laboratory to launch the Vectra Polaris system for image analysis of circulating tumor cells following ApoStream’s isolation and enrichment functionality,” said Darren Davis, PhD, Precision for Medicine Senior Vice President. “Together, these technologies will enable accelerated drug development through detection of biomarkers in liquid biopsies. These tools have enabled our scientists to better understand the biological correlation of circulating metastatic cancer cells with cancer cells present in the tumor tissue.”
Circulating tumor cells (CTCs) have long been known to exist in cancer patients’ blood. However, the promise of clinical application of CTCs as a liquid biopsy has not born fruit because these cells are difficult to detect using current molecular biology techniques. Precision for Medicine’s proprietary ApoStream technology captures significant quantities of rare circulating cancer cells from whole blood for characterization using Akoya’s Opal™ technology and Vectra Polaris imaging platform. ApoStream has been used in more than 80 clinical trials, including several ongoing phase III studies for CDx development.
Akoya’s Vectra Polaris Automated Quantitative Pathology System, part of the company’s Phenoptics 2.0 next-generation biomarker multiplexing platform, enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches. The Vectra Polaris system integrates high throughput, seven-color multispectral imaging with whole-slide scanning in a simplified digital pathology workflow to support the quantification and analysis of tissue sections discernible with Opal detection kits. A recent meta-analysis of several studies showed that incorporating spatial information using Akoya’s multiplexed immunofluorescence technology is important for improving the predictive accuracy of immuno-oncology biomarkers.
The Phenoptics™ portfolio is capable of interrogating multiple protein markers on any tissue or cytology slide preparation. Precision for Medicine has validated several immune biomarker panels across various therapeutic applications using both types of preparation. These immune panels are currently being used to monitor immune cell infiltration including cancer, psoriasis, lupus and atomic dermatitis.
“The Vectra Polaris imaging system offers an innovative approach to assessing immunotherapy candidates in translational and clinical research,” said Dr. Cliff Hoyt, Akoya Vice President of Translational and Scientific Affairs. “We are pleased to see this technology paired with ApoStream for a comprehensive method of imaging CTCs and improving our understanding of disease mechanisms in cancer.”
For more information on ApoCell and the ApoStream technology, please click here.
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with more than 1,900 employees in 34 locations in the US, Canada, and Europe. For more information, visit www.PrecisionForMedicine.com.
Akoya Biosciences, The Spatial Biology Company™, offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and other immune system or neurological disorders. The CODEX® system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics™ platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials. For more information, please visit https://www.akoyabio.com/.
Media Contact – Precision for Medicine
Louis Landon, Precision Medicine Group Media Relations
Media Contact – Akoya
Michelle Linn, Bioscribe, Inc.